ArriVent BioPharma (NASDAQ:AVBP) Receives New Coverage from Analysts at HC Wainwright

Stock analysts at HC Wainwright started coverage on shares of ArriVent BioPharma (NASDAQ:AVBP) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 49.79% from the stock’s current price.

Several other brokerages have also commented on AVBP. Jefferies Financial Group started coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $35.00 price target for the company. The Goldman Sachs Group started coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $27.00 price target for the company. Finally, Citigroup started coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They set a “buy” rating and a $30.00 price target for the company.

ArriVent BioPharma Trading Up 1.0 %

Shares of AVBP opened at $16.69 on Tuesday. The firm’s 50 day moving average price is $18.12. ArriVent BioPharma has a 1 year low of $14.35 and a 1 year high of $25.95.

Hedge Funds Weigh In On ArriVent BioPharma

A hedge fund recently bought a new stake in ArriVent BioPharma stock. BNP Paribas Financial Markets acquired a new stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,659 shares of the company’s stock, valued at approximately $83,000. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.